VRTX:NSD-Vertex Pharmaceuticals Incorporated (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 205.22

Change

+0.16 (+0.08)%

Market Cap

USD 51.82B

Volume

1.87M

Avg Analyst Target

USD 241.70 (+17.77%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Vertex Pharmaceuticals Incorporated (VRTX) Stock Analysis:
Based on the Vertex Pharmaceuticals Incorporated stock forecasts from 15 analysts, the average analyst target price for Vertex Pharmaceuticals Incorporated is USD 241.70 over the next 12 months. Vertex Pharmaceuticals Incorporated’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Vertex Pharmaceuticals Incorporated is Bullish , which is based on 10 positive signals and 4 negative signals. At the last closing, Vertex Pharmaceuticals Incorporated’s stock price was USD 205.22. Vertex Pharmaceuticals Incorporated’s stock price has changed by +18.28 % over the past week, +12.37 % over the past month and -10.71 % over the last year.

About

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembra ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+17.02 (+6.41%)

USD122.24B 18.38 14.64
BNTX BioNTech SE

+22.86 (+8.17%)

USD83.44B 8.87 7.65
REGN Regeneron Pharmaceuticals Inc

+10.09 (+1.61%)

USD68.31B 10.00 7.78
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

+18.04 (+6.03%)

USD33.26B N/A N/A
SGEN Seagen Inc

+0.43 (+0.29%)

USD27.56B 55.02 44.86
GMAB Genmab A/S

+1.82 (+4.93%)

USD24.43B 55.83 6.05
ALNY Alnylam Pharmaceuticals Inc

+3.28 (+1.85%)

USD20.49B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
TECH Bio-Techne Corporation

+4.72 (+1.01%)

USD17.92B 107.96 64.40

ETFs Containing VRTX

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.17% 66% D 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.17% 66% D 31% F
Trailing 12 Months  
Capital Gain -10.71% 67% D+ 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.71% 67% D+ 30% F
Trailing 5 Years  
Capital Gain 165.76% 78% C+ 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 165.76% 78% C+ 80% B-
Average Annual (5 Year Horizon)  
Capital Gain 19.08% 56% F 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.08% 56% F 64% D
Risk Return Profile  
Volatility (Standard Deviation) 32.02% 82% B- 56% F
Risk Adjusted Return 59.58% 88% B+ 77% C+
Market Capitalization 51.82B 99% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 24.59 29% F 36% F
Price/Book Ratio 5.44 24% F 23% F
Price / Cash Flow Ratio 15.93 5% F 26% F
EV/EBITDA 15.60 23% F 44% F
Management Effectiveness  
Return on Equity 24.64% 98% A+ 90% A-
Return on Invested Capital 33.19% 93% A 94% A
Return on Assets 13.85% 98% A+ 96% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.69 75% C 65% D
Short Percent 1.14% 85% B 71% C-
Beta 0.60 79% C+ 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.